Pharmacy and Pharmaceutical Sciences Commons^™

Pharmacokinetics Of Intraperitoneal Vancomycin In Patients On Automated Peritoneal Dialysis, Edwin Lam, Yi Ting Kayla Lien, Valvanera Vozmediano, Stephan Schmidt, Walter K. Kraft, Jingjing Zhang

Department of Pharmacology and Experimental Therapeutics Posters

Primary Objective

• Characterize the pharmacokinetics of vancomycin in plasma, dialysate, and urine following a single intraperitoneal dose

Secondary Objective

• Explore the safety, tolerability, and feasibility in administering vancomycin during the long dwell period in patients on APD

Population Pharmacokinetic And Pharmacodynamic Analysis Of Buprenorphine For The Treatment Of Neonatal Abstinence Syndrome, Jason N. Moore, Pharmd, Marc Gastonguay, Susan C. Adeniyi-Jones, Md, David E. Moody, Walter K. Kraft, Md, Facp

Department of Pharmacology and Experimental Therapeutics Posters

Neonatal abstinence syndrome (NAS) is a condition affecting newborns exposed to an opioid in utero. Symptoms of NAS include excessive crying, poor feeding, and disordered autonomic control. Up to 2/3 of infants will require pharmacologic therapies to reach symptom control. Opioids including morphine and methadone are the current first-line treatments. Buprenorphine is being investigated as a treatment of NAS. The purpose of this analysis was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of BUP in infants with NAS.

Poster presented at American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2017 Annual Meeting, March 15-18, 2017 in Washington DC.

A Phase I Study Of Ad5-Gucy2c-Padre In Stage I And Ii Colon Cancer Patients, Adam E. Snook, Trevor R. Baybutt, Michael J. Mastrangelo, Nancy L. Lewis, Scott D. Goldstein, Walter K. Kraft, Yaa D. Oppong, Terry Hyslop, Ronald E. Myers, Vitali Alexeev, Laurence C. Eisenlohr, Takami Sato, Scott A. Waldman

Department of Pharmacology and Experimental Therapeutics Posters

Background

Ad5-GUCY2C-PADRE is a replication-deficient human type 5 recombinant adenovirus (Ad5) vaccine encoding guanylyl cyclase C (GUCY2C) fused to the PAn DR Epitope (PADRE). GUCY2C, a paracrine hormone receptor producing the second messenger cyclic GMP (cGMP), is selectively expressed by intestinal epithelial cells and a subset of hypothalamic neurons, but not other tissues. Importantly, GUCY2C is over-expressed in nearly all primary and metastatic human colorectal tumors. Preclinical studies in mice demonstrated selective tolerance of GUCY2C-specific CD4+ T cells, but not CD8+ T or B cells, necessitating inclusion of the exogenous CD4+ T helper cell epitope PADRE to maximize GUCY2C-specific CD8+ …

Ethanol Pharmacokinetics In Neonates Secondary To Medication Administration, Elizabeth Marek, Pharmd, Susan C. Adeniyi-Jones, Md, Lindsey Roke, Pharmd, Tara E. Decerbo, Pharmd, Rebecca L. Cordell, Pharmd, Paul S. Monks, Pharmd, Walter K. Kraft, Md

Department of Pharmacology and Experimental Therapeutics Posters

Purpose:

Ethanol serves as a solvent and microbial preservative in oral liquid medications and is the second most commonly used solvent in liquid medications following water. Despite widespread use of ethanol in liquid medications for neonates, the pharmacokinetics and toxicity of ethanol in young children are not well described. The aim of the current study is to quantify blood ethanol levels in neonates secondary to oral ethanol containing medications.

Methods:

Neonates who received either oral phenobarbital (15% ethanol) and/or oral dexamethasone (30% ethanol) per standard of care were eligible for enrollment. A maximum of 6 blood samples per patient (4.5 …

Neonatal Abstinence Syndrome In Methadone Exposed Infants: Role Of Genetic Variability, Andrea L. Fielder, J. K. Coller, M. R. Hutchinson, Ross R. Haslam, Nona Lu, Susan C. Adeniyi-Jones, Michelle Ehrlich, Walter K. Kraft

Department of Pharmacology and Experimental Therapeutics Posters

Poster presented at: CPDD Scientific Meeting, San Juan, PR.

Aims: NAS incidence & severity in infants exposed to methadone during gestation is independent of maternal methadone dose. The incidence & severity of NAS could be in part due to genetic variability of key genetic loci related to opioid response; the interleukin-1beta (IL-1B) & mu opioid receptor (OPRM1) genes. This study aimed to investigate the impact of genetic variability in IL-1B -31 or OPRM1 A118G on NAS incidence (treatment required) & severity (dose of morphine).

Methods: This pilot study collected cheek cells from 71 methadone exposed infants; 46 …